688331 荣昌生物
已收盘 06-18 15:00:01
资讯
新帖
简况
荣昌生物(09995)：王威东获重选为董事会董事长
智通财经 · 06-16 22:24
荣昌生物(09995)：王威东获重选为董事会董事长
荣昌生物（688331）披露2025年年度股东会决议公告，6月16日股价下跌4.22%
证券之星 · 06-16 22:06
荣昌生物（688331）披露2025年年度股东会决议公告，6月16日股价下跌4.22%
荣昌生物：公司尚无药品在欧盟获批上市，无药品向欧盟出口销售
证券之星 · 06-12
荣昌生物：公司尚无药品在欧盟获批上市，无药品向欧盟出口销售
荣昌生物：辉瑞会计处理不会影响合作权益
证券之星 · 06-12
荣昌生物：辉瑞会计处理不会影响合作权益
荣昌生物：维迪西妥单抗的海外合作仍在积极推进中
证券之星 · 06-12
荣昌生物：维迪西妥单抗的海外合作仍在积极推进中
荣昌生物涨8.28%，东海证券二个月前给出“买入”评级
证券之星 · 06-12
荣昌生物涨8.28%，东海证券二个月前给出“买入”评级
医药板块集体回升 科伦博泰生物(06990)涨7.20%、荣昌生物(09995)涨6.53%
金吾财讯 · 06-12
医药板块集体回升 科伦博泰生物(06990)涨7.20%、荣昌生物(09995)涨6.53%
荣昌生物涨5.07%，东海证券二个月前给出“买入”评级
证券之星 · 06-09
荣昌生物涨5.07%，东海证券二个月前给出“买入”评级
港股异动 | 荣昌生物(09995)盘中涨超5%泰它西普两大适应症同日获批
智通财经 · 06-09
港股异动 | 荣昌生物(09995)盘中涨超5%泰它西普两大适应症同日获批
荣昌生物：注射用泰它西普新适应症获国家药监局批准用于治疗干燥综合征
美股速递 · 06-08
荣昌生物：注射用泰它西普新适应症获国家药监局批准用于治疗干燥综合征
荣昌生物：注射用泰它西普治疗干燥综合征上市申请获批
财中社 · 06-08
荣昌生物：注射用泰它西普治疗干燥综合征上市申请获批
荣昌生物(09995)拟以3亿元的闲置自有资金向浦发银行烟台分行购买理财产品
智通财经 · 06-01
荣昌生物(09995)拟以3亿元的闲置自有资金向浦发银行烟台分行购买理财产品
荣昌生物涨6.50%，东海证券一个月前给出“买入”评级
证券之星 · 05-29
荣昌生物涨6.50%，东海证券一个月前给出“买入”评级
东方证券减持荣昌生物(09995)16万股 每股均价约84.83港元
智通财经 · 05-26
东方证券减持荣昌生物(09995)16万股 每股均价约84.83港元
荣昌生物(09995)进一步购买6000万元的华泰证券理财产品
智通财经 · 05-26
荣昌生物(09995)进一步购买6000万元的华泰证券理财产品
荣昌生物遭汇添富基金减持16万股 每股作价约84.83港元
新浪港股 · 05-24
荣昌生物遭汇添富基金减持16万股 每股作价约84.83港元
每周股票复盘：荣昌生物（688331）变更募投项目并调整注册资本
证券之星 · 05-24
每周股票复盘：荣昌生物（688331）变更募投项目并调整注册资本
汇添富基金减持荣昌生物(09995)16万股 每股作价约84.83港元
智通财经 · 05-22
汇添富基金减持荣昌生物(09995)16万股 每股作价约84.83港元
荣昌生物董事长王威东：国内销售、海外授权双向赋能丨21健谈
21世纪经济报道 · 05-20
荣昌生物董事长王威东：国内销售、海外授权双向赋能丨21健谈
荣昌生物同意从华泰证券等机构购买1500万元理财产品
美股速递 · 05-19
荣昌生物同意从华泰证券等机构购买1500万元理财产品
加载更多
公司概况
公司名称：
荣昌生物制药(烟台)股份有限公司
所属行业：
医药制造业
上市日期：
2022-03-31
主营业务：
荣昌生物制药(烟台)股份有限公司的主营业务是研发、生产和销售医药产品、诊断试剂产品。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC148、RC278、RC288。
发行价格：
48.00
{"stockData":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":114.48,"timestamp":1781766001000,"preClose":109.19,"halted":0,"volume":12290223,"delay":0,"changeRate":0.0484,"floatShares":163000000,"shares":564000000,"eps":2.2885,"marketStatus":"已收盘","change":5.29,"latestTime":"06-18 15:00:01","open":107.53,"high":119.56,"low":106,"amount":1402000000,"amplitude":0.1242,"askPrice":114.5,"askSize":15,"bidPrice":114.48,"bidSize":23,"shortable":0,"etf":0,"ttmEps":2.2885,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782091800000},"marketStatusCode":5,"adr":0,"adjPreClose":109.19,"symbolType":"stock_kcb","openAndCloseTimeList":[[1781746200000,1781753400000],[1781758800000,1781766000000]],"highLimit":120.11,"lowLimit":98.27,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":564477483,"isCdr":false,"pbRate":16.45,"roa":"--","peRate":50.024033,"roe":"8.68%","epsLYR":1.29,"committee":0.25,"marketValue":64621000000,"turnoverRate":0.0754,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-06-22。","afterMarket":{"amount":22896,"volume":200,"close":114.48,"buyVolume":900,"sellVolume":0,"time":1781768037746,"indexStatus":"已收盘 06-18 15:30:00","preClose":109.19},"hkstockBrief":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":68.5,"timestamp":1781770088010,"preClose":67.4,"halted":0,"volume":6997000,"delay":0,"premium":"-48.18"},"floatMarketCap":18671000000},"requestUrl":"/m/hq/s/688331","defaultTab":"news","newsList":[{"id":"2643376396","title":"荣昌生物(09995)：王威东获重选为董事会董事长","url":"https://stock-news.laohu8.com/highlight/detail?id=2643376396","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643376396?lang=zh_cn&edition=full","pubTime":"2026-06-16 22:24","pubTimestamp":1781619849,"startTime":"0","endTime":"0","summary":"公司于2026年6月16日召开职工代表大会，经民主选举，王玉晓先生获选为第三届董事会职工代表董事。于2026年6月16日举行的第三届董事会第一次会议上，已议决：王威东先生获重选为第三届董事会董事长;房健民博士获重选为公司首席执行官，上述各项任期自年度股东会日期起计为期三年，直至第三届董事会任期届满为止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455220.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064131003.USD","BK1161","LU2328871848.SGD","LU2148510915.USD","LU1064130708.USD","688331","LU2488822045.USD","LU1969619763.USD","09995","BK0239","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643890763","title":"荣昌生物（688331）披露2025年年度股东会决议公告，6月16日股价下跌4.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643890763","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643890763?lang=zh_cn&edition=full","pubTime":"2026-06-16 22:06","pubTimestamp":1781618781,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，荣昌生物报收于107.4元，较前一交易日下跌4.22%，最新总市值为606.25亿元。该股当日开盘111.5元，最高111.99元，最低106.53元，成交额达8.35亿元，换手率为4.74%。近日，荣昌生物制药（烟台）股份有限公司披露《2025年年度股东会决议公告》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600043963.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","BK1161","LU2488822045.USD","LU1969619763.USD","LU2148510915.USD","BK1583","BK0239","LU2328871848.SGD","LU1064131003.USD","LU1064130708.USD","09995","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642430261","title":"荣昌生物：公司尚无药品在欧盟获批上市，无药品向欧盟出口销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2642430261","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642430261?lang=zh_cn&edition=full","pubTime":"2026-06-12 17:45","pubTimestamp":1781257538,"startTime":"0","endTime":"0","summary":"证券之星消息，荣昌生物(688331)06月12日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司近年是否存在向欧盟成员国出口或销售的相关业务？如有，欧盟地区业务收入在公司整体营业收入中的占比大致为多少？此外，公司对欧盟市场的销售主要通过哪种方式实现：是以境内主体直接向欧盟客户出口为主，还是通过在欧盟国家设立的子公司进行销售，或通过第三方贸易商、代理商转销至欧盟市场？荣昌生物回复：尊敬的投资者您好，公司尚无药品在欧盟获批上市，无药品向欧盟出口销售，未来业务的开展情况，还请您关注公司的相关公告，感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200028056.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","LU2328871848.SGD","BK1583","BK0239","FESXmain","FSXEmain","LU2488822045.USD","LU1969619763.USD","BK1161","LU2148510915.USD","LU1064131003.USD","09995","LU1064130708.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642261142","title":"荣昌生物：辉瑞会计处理不会影响合作权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2642261142","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642261142?lang=zh_cn&edition=full","pubTime":"2026-06-12 17:45","pubTimestamp":1781257523,"startTime":"0","endTime":"0","summary":"公司与辉瑞就维迪西妥单抗合作的里程碑付款及销售分成等权益，均由双方签署的协议条款所约定，辉瑞方面的相关会计处理不会影响上述合作权益。目前辉瑞正在推进的临床试验进展，还请关注合作伙伴的官方披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200028042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","688331","LU1064131003.USD","09995","BK1574","BK1161","LU2148510915.USD","LU2328871848.SGD","BK1583","LU1969619763.USD","LU2488822045.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642261466","title":"荣昌生物：维迪西妥单抗的海外合作仍在积极推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2642261466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642261466?lang=zh_cn&edition=full","pubTime":"2026-06-12 17:45","pubTimestamp":1781257522,"startTime":"0","endTime":"0","summary":"证券之星消息，荣昌生物(688331)06月12日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵司维迪西妥单抗目前与辉瑞合作的，目前只剩下一线还在临床中，其他的比如二线，是否辉瑞已经放弃？贵司去年年初曾说，二线在为辉瑞准备资料BLA，年报以及今年一季报都未提及二线未来方向，是否已经被辉瑞放弃？请给出明确答复荣昌生物回复：尊敬的投资者，您好！维迪西妥单抗的海外合作仍在积极推进中，公司将持续配合辉瑞做好相关支持工作，关于海外临床的具体进展，请关注辉瑞的官方披露。感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200028038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","09995","LU2148510915.USD","LU1969619763.USD","BK0239","BK1583","LU1064130708.USD","LU1064131003.USD","LU2328871848.SGD","BK1161","BK1574","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642659282","title":"荣昌生物涨8.28%，东海证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2642659282","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642659282?lang=zh_cn&edition=full","pubTime":"2026-06-12 16:29","pubTimestamp":1781252941,"startTime":"0","endTime":"0","summary":"今日荣昌生物涨8.28%，收盘报113.9元。2026年4月3日，东海证券研究员杜永宏,付婷发布了对荣昌生物的研报《公司简评报告：商业化+BD驱动高增长，创新研发快速推进》，该研报对荣昌生物给出“买入”评级。公司经营效率不断提升，国际化进程加速，维持“买入”评级。荣昌生物个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200025375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09995","161027","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642254781","title":"医药板块集体回升 科伦博泰生物(06990)涨7.20%、荣昌生物(09995)涨6.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642254781","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642254781?lang=zh_cn&edition=full","pubTime":"2026-06-12 13:30","pubTimestamp":1781242214,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药板块集体回升，科伦博泰生物 涨7.20%，荣昌生物涨6.53%，康诺亚-B涨5.58%，复宏汉霖涨5.36%，康方生物涨5.07%，君实生物涨4.61%，药明合联涨4.06%，诺诚健华涨3.96%。英伟达同时为 Abridge 投资方，新模型基于英伟达开放模型套件 Nemotron 训练，Abridge 将采用去标识化临床数据进行定制优化，预计 2026 年晚些时候上线。东莞证券研报认为，受行业合规整顿以及消费疲软等因素影响，2025年医药生物行业整体归母净利润同比有所下滑。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983673","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969","LU2148510915.USD","HK0000306701.USD","BK1574","BK1161","LU1794554557.SGD","LU0348825331.USD","09939","HK0000320264.USD","LU0417516738.SGD","LU0348767384.USD","02268","LU0348735423.USD","LU1720050803.USD","09926","LU2476274720.SGD","BK0239","LU1064130708.USD","HK0000165453.HKD","LU0634319403.HKD","IE00BPRC5H50.USD","LU1961090484.USD","09995","SG9999014674.SGD","06990","LU1064131003.USD","LU0348827113.USD","LU2476274308.USD","BK1583","LU2328871848.SGD","HK0000320223.HKD","BK1141","LU0348783233.USD","LU0540923850.HKD","BK1515","LU0348784397.USD","LU2488822045.USD","02696","LU2399975544.HKD","LU0417516902.SGD","01877","159938","BK1587","HK0000306685.HKD","LU1969619763.USD","688331","LU0348766576.USD","LU0417516571.SGD","LU0561508036.HKD","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642463933","title":"荣昌生物涨5.07%，东海证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2642463933","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642463933?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:42","pubTimestamp":1780994575,"startTime":"0","endTime":"0","summary":"今日荣昌生物涨5.07%，收盘报102.41元。2026年4月3日，东海证券研究员杜永宏,付婷发布了对荣昌生物的研报《公司简评报告：商业化+BD驱动高增长，创新研发快速推进》，该研报对荣昌生物给出“买入”评级。公司经营效率不断提升，国际化进程加速，维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为23.03%。荣昌生物个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900027049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","161027","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642783455","title":"港股异动 | 荣昌生物(09995)盘中涨超5%泰它西普两大适应症同日获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2642783455","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642783455?lang=zh_cn&edition=full","pubTime":"2026-06-09 10:29","pubTimestamp":1780972163,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物(09995)盘中涨超5%，截至发稿，涨3.78%，报71.3港元，成交额2.58亿港元。消息面上，6月8日，荣昌生物宣布，公司自主研发的全球首创BLyS/APRIL双靶点融合蛋白创新药泰它西普（RC18）治疗干燥综合征（干燥病）、IgA肾病的两项新适应症获国家药品监督管理局（NMPA）批准上市，标志着干燥综合征领域迎来了全球首个获批的生物制剂，同时开启了精准治疗IgA肾病新时代。至此，泰它西普已有系统性红斑狼疮、类风湿关节炎、全身型重症肌无力、干燥综合征（干燥病）、IgA肾病等五个适应症在国内获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451803.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","LU1064131003.USD","VXUS","BK1574","09995","BK0239","688331","BK1161","BK1583","LU2328871848.SGD","LU2148510915.USD","BK4585","LU2488822045.USD","LU1064130708.USD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124118507","title":"荣昌生物：注射用泰它西普新适应症获国家药监局批准用于治疗干燥综合征","url":"https://stock-news.laohu8.com/highlight/detail?id=1124118507","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124118507?lang=zh_cn&edition=full","pubTime":"2026-06-08 19:45","pubTimestamp":1780919144,"startTime":"0","endTime":"0","summary":"荣昌生物宣布，其核心产品注射用泰它西普用于治疗干燥综合征的新适应症，已正式获得中国国家药品监督管理局的上市批准。此次获批标志着泰它西普在自身免疫疾病治疗领域的又一重要拓展。新适应症的获批，为国内广大干燥综合征患者提供了一种全新的治疗选择。此次新增适应症，有望进一步拓宽其市场潜力，巩固公司在自身免疫疾病治疗领域的领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688331","LU2148510915.USD","LU2488822045.USD","LU1064131003.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641485599","title":"荣昌生物：注射用泰它西普治疗干燥综合征上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2641485599","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641485599?lang=zh_cn&edition=full","pubTime":"2026-06-08 18:22","pubTimestamp":1780914120,"startTime":"0","endTime":"0","summary":"6月8日，荣昌生物（688331/09995）发布公告，公司收到国家药品监督管理局核准签发的药品注册证书，注射用泰它西普治疗干燥综合征（干燥病）的新适应症上市申请获批。泰它西普是公司自主研发的全球首个BLyS/APRIL双靶点创新药，通过同时抑制BLyS和APRIL与B细胞表面受体结合，阻断B细胞异常分化和成熟，更好地控制疾病活动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606083763744625.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","LU1064131003.USD","688331","BK1161","LU2148510915.USD","BK1574","LU2328871848.SGD","BK0239","09995","IPOS","LU2488822045.USD","LU1969619763.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640932958","title":"荣昌生物(09995)拟以3亿元的闲置自有资金向浦发银行烟台分行购买理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2640932958","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640932958?lang=zh_cn&edition=full","pubTime":"2026-06-01 16:46","pubTimestamp":1780303573,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物(09995)发布公告，于2026年6月1日，本公司进一步与浦发银行烟台分行订立浦发银行理财产品8号协议，据此本公司同意以人民币3亿元的闲置自有资金向浦发银行烟台分行购买理财产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448495.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1969619763.USD","LU0469268626.HKD","BK0188","LU1064131003.USD","LU1808992512.USD","LU1979443071.USD","BK0183","BK0201","SGXZ49509284.SGD","BK0239","09995","BK0086","BK1574","LU2488822045.USD","BK1161","BK0278","BK0187","600000","SGXZ81163826.USD","BK0012","BK1583","688331","LU1934453819.USD","LU2328871848.SGD","BK0028","BK0015","LU1064130708.USD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639628589","title":"荣昌生物涨6.50%，东海证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2639628589","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639628589?lang=zh_cn&edition=full","pubTime":"2026-05-29 16:38","pubTimestamp":1780043890,"startTime":"0","endTime":"0","summary":"今日荣昌生物涨6.50%，收盘报116.03元。2026年4月3日，东海证券研究员杜永宏,付婷发布了对荣昌生物的研报《公司简评报告：商业化+BD驱动高增长，创新研发快速推进》，该研报对荣昌生物给出“买入”评级。公司经营效率不断提升，国际化进程加速，维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为23.03%。荣昌生物个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900030222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","09995","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638197575","title":"东方证券减持荣昌生物(09995)16万股 每股均价约84.83港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2638197575","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638197575?lang=zh_cn&edition=full","pubTime":"2026-05-26 19:30","pubTimestamp":1779795004,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，5月19日，东方证券减持荣昌生物(09995)16万股，每股均价84.8306港元，总金额约为1357.29万港元。减持后最新持股数目为1037.45万股，最新持股比例为4.97%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446169.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","BK1147","BK0028","BK0183","BK1564","BK0276","EWH","LU2488822045.USD","688331","BK0239","600958","BK0012","LU1969619763.USD","BK1574","BK0188","09995","LU1064130708.USD","BK1583","LU2328871848.SGD","03958","LU1064131003.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638926345","title":"荣昌生物(09995)进一步购买6000万元的华泰证券理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2638926345","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638926345?lang=zh_cn&edition=full","pubTime":"2026-05-26 16:36","pubTimestamp":1779784596,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物(09995)发布公告，于2026年5月26日，本公司进一步与华泰证券订立华泰证券理财产品9号协议，据此本公司同意以人民币6000万元的闲置自有资金向华泰证券购买理财产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0531971595.HKD","LU1064130708.USD","LU1979443071.USD","BK0028","LU0164865239.USD","LU1580142542.USD","LU1781817850.SGD","BK1583","LU1328615791.USD","BK0188","LU0039217434.USD","BK0012","BK1574","LU1969619763.USD","LU1808992512.USD","LU2148510915.USD","601688","LU2328871848.SGD","LU1064131003.USD","LU1934453819.USD","LU0871576103.HKD","688331","BK0183","09995","LU2488822045.USD","BK1161","BK0276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637086893","title":"荣昌生物遭汇添富基金减持16万股 每股作价约84.83港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2637086893","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637086893?lang=zh_cn&edition=full","pubTime":"2026-05-24 16:30","pubTimestamp":1779611400,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 香港联交所最新资料显示，5月19日，汇添富基金减持荣昌生物（09995）16万股，每股作价84.8306港元，总金额约为1357.29万港元。减持后最新持股数目为1037.45万股，最新持股比例为4.97%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-05-24/doc-inhyytnn4398818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1064130708.USD","BK1574","LU1064131003.USD","09995","LU1969619763.USD","BK1161","LU2328871848.SGD","BK1583","EWH","LU2488822045.USD","BK0239","688331","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637378691","title":"每周股票复盘：荣昌生物（688331）变更募投项目并调整注册资本","url":"https://stock-news.laohu8.com/highlight/detail?id=2637378691","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637378691?lang=zh_cn&edition=full","pubTime":"2026-05-24 01:17","pubTimestamp":1779556631,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，荣昌生物报收于116.7元，较上周的114.66元上涨1.78%。公司公告汇总荣昌生物第二届董事会第三十八次会议审议通过多项议案，包括部分募投项目子项目变更及金额调整、董事会换届选举非独立董事和独立董事候选人、变更注册资本并修订公司章程、修订及制定部分内部管理制度，并提请召开2025年年度股东会。荣昌生物拟对A股首次公开发行募集资金投资项目中的“抗肿瘤抗体新药研发项目”部分临床试验子项目进行调整。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400000123.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK1583","BK1574","BK1161","LU1969619763.USD","BK0239","688331","09995","LU1064130708.USD","LU2328871848.SGD","LU2488822045.USD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637831217","title":"汇添富基金减持荣昌生物(09995)16万股 每股作价约84.83港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2637831217","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637831217?lang=zh_cn&edition=full","pubTime":"2026-05-22 20:49","pubTimestamp":1779454173,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，5月19日，汇添富基金减持荣昌生物(09995)16万股，每股作价84.8306港元，总金额约为1357.29万港元。减持后最新持股数目为1037.45万股，最新持股比例为4.97%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445275.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064130708.USD","BK0239","BK1583","LU2148510915.USD","LU1969619763.USD","LU2328871848.SGD","EWH","BK1574","LU2488822045.USD","09995","LU1064131003.USD","688331","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636881660","title":"荣昌生物董事长王威东：国内销售、海外授权双向赋能丨21健谈","url":"https://stock-news.laohu8.com/highlight/detail?id=2636881660","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636881660?lang=zh_cn&edition=full","pubTime":"2026-05-20 14:46","pubTimestamp":1779259586,"startTime":"0","endTime":"0","summary":"2026年一季度创新药企业绩成绩单出炉，荣昌生物（688331.SH/9995.HK）经营成效显著。数据显示，报告期内荣昌生物营收6.56亿元，同比增长24.76%，归母净利润3.28亿元，较上年同期成功扭亏为盈。对于创业十八年的老牌企业荣昌生物而言，盈利意味着战略姿态的主动化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605203743371973.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605203743371973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2328871848.SGD","09995","688331","LU2488822045.USD","LU2148510915.USD","LU1969619763.USD","BK1583","BK0239","LU1064130708.USD","BK1161","BK1574","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125330267","title":"荣昌生物同意从华泰证券等机构购买1500万元理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=1125330267","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125330267?lang=zh_cn&edition=full","pubTime":"2026-05-19 19:21","pubTimestamp":1779189674,"startTime":"0","endTime":"0","summary":"荣昌生物宣布，已达成协议，将从华泰证券及其他相关方购入价值总计1500万元人民币的理财产品。此项财务安排旨在优化公司闲置资金管理，提升资金使用效率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131003.USD","LU2488822045.USD","688331","LU2148510915.USD","LU1064130708.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1781862615122,"stockEarnings":[{"period":"1week","weight":0.0883},{"period":"1month","weight":0.0179},{"period":"3month","weight":-0.0193},{"period":"6month","weight":0.3893},{"period":"1year","weight":0.8151},{"period":"ytd","weight":0.4717}],"compareEarnings":[{"period":"1week","weight":0.026},{"period":"1month","weight":-0.019},{"period":"3month","weight":0.0337},{"period":"6month","weight":0.0514},{"period":"1year","weight":0.2071},{"period":"ytd","weight":0.0306}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"荣昌生物制药(烟台)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"19720人(较上一季度增加12.97%)","perCapita":"8270股","listingDate":"2022-03-31","address":"山东省烟台市福山区中国(山东)自由贸易试验区烟台片区烟台开发区北京中路58号","registeredCapital":"56447万元","survey":" 荣昌生物制药(烟台)股份有限公司的主营业务是研发、生产和销售医药产品、诊断试剂产品。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC148、RC278、RC288。","listedPrice":48},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,688331,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}